The Predictive Value of 2D Myocardial Strain for Epirubicin-Induced Cardiotoxicity

Table 3

Univariate analysis of baseline parameters and clinical features of patients who did or did not present with cardiotoxicity during follow-up.

	All patients (n = 66)	CTRCD+ (n = 5)	CTRCD-(n = 61)	value
Age, years, median [ranges]	46 [27–70]	45 [42–47]	47 [27–70]	0.125
Epirubicin cumulative dose (mg/m^2), median [ranges]	350 [200–900]	600 [400–900]	300 [200–900]	0.001
LVEF T0 (%), median [ranges]	70 [58–75]	67 [62–75]	70 [58–75]	0.670
GLS T0 (%), median [ranges]	−21 [−25, −18]	−21 [−22, −19]	−21 [−25, −18]	0.597
Adjuvant LRR for left-sided BC, n (%)	27 (41%)	1 (20%)	26 (42%)	0.323
Cancer stage:				0.098
Early disease, n (%)	56 (85%)	2 (40%)
Metastatic disease, n (%)	10 (15%)	3 (60%)

CTRCD+: patients who presented with cardiotoxicity during follow-up. T0: at baseline. CTRCD-: patients who did not present with cardiotoxicity during follow-up. T3: at three months. GLS: global longitudinal strain. LVEF: left ventricular ejection fraction. LRR: locoregional radiotherapy. BC: breast cancer. Ps: as patients A and B already presented with CTRCD before T3, they were excluded from further analysis.